1.
JACC Basic Transl Sci
; 3(2): 200-209, 2018 Apr.
Artículo
en Inglés
| MEDLINE
| ID: mdl-30062205
RESUMEN
Even the most advanced drug-eluting stents evoke unresolved issues, including chronic inflammation, late thrombosis, and neoatherosclerosis. This highlights the need for novel strategies that improve stent biocompatibility. Our studies show that apolipoprotein A-I (apoA-I) reduces in-stent restenosis and platelet activation, and enhances endothelialization. These findings have therapeutic implications for improving stent biocompatibility.